2023 World Conference on Lung Cancer (Posters)-EP10.01. Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital

EP10.01. Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital - PDF(Slides)

Back to course

Pdf Summary

FAUGET, a study conducted at Dr. Cipto Mangunkusumo General Hospital in Jakarta, Indonesia, aimed to analyze the clinical characteristics, systemic anti-cancer therapy patterns, and overall survival of patients with stage IV non-small cell lung cancer (NSCLC). The study included patients diagnosed from January 2014 to December 2019 who were 18 years and older. The most common subtype of NSCLC was adenocarcinoma, and common comorbidities included pneumonia, hypertension, and coronary heart disease.<br /><br />The study found that the most common first-line chemotherapy regimen was platinum taxanes, while the most common first-line targeted therapy was Gefitinib. The median survival for patients who did not receive treatment was one month compared to 12 months for treated patients. The median survival for patients receiving chemotherapy versus targeted therapy was 11 months and 16 months, respectively.<br /><br />The study concluded that the demographic characteristics of patients with metastatic NSCLC were similar to those in other studies. Pneumonia, hypertension, coronary heart disease, and diabetes mellitus were the most common comorbidities. Platinum taxanes were commonly used for systemic therapy, while gefitinib was the preferred choice for targeted therapy. The targeted therapy group demonstrated the most favorable survival outcomes, followed by the systemic chemotherapy group.<br /><br />Overall, the study highlights the importance of multidisciplinary teams involving medical oncologists, pulmonologists, thoracic surgeons, radiation oncologists, radiologists, and anatomical pathologists in the diagnosis and treatment of stage IV NSCLC. The advancement of chemotherapy, targeted therapy, and immunotherapy is improving the systemic treatment of NSCLC and aiming to control symptoms, improve quality of life, and prolong survival.

Asset Subtitle

Wulyo Rajabto

Meta Tag

Speaker Wulyo Rajabto

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

FAUGET

study

NSCLC

chemotherapy

targeted therapy

survival

comorbidities

pneumonia

hypertension

coronary heart disease